Disease Protein Production Small Molecule 
Dark Matter Blog
JULY 16, 2021
My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.
Drug Discovery World
NOVEMBER 17, 2022
Advances in this field have progressed significantly in the last 50 years or so and show promise in the quest to tackle a range of diseases and illnesses. Antibiotic drug discovery once largely consisted of scientists growing streptomyces or bacillus in the lab and bottling their secrets to treat human disease. . Designer cells .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 23, 2022
Unfortunately, in a Phase 3 clinical trial, treatment with remdesivir did not make a difference in mortality for Ebola virus disease patients. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang.
Drug Discovery World
APRIL 30, 2024
Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. Its job is to carry coding information that is essential to the translation and processing of functional proteins.
Drug Discovery World
JANUARY 12, 2023
Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . CRISPR allows researchers to target and edit specific genes in order to better understand the genome, human diseases and the effects of specific mutations.
Drug Discovery World
NOVEMBER 13, 2023
Jens Fischer, PhD, Program Manager, Large Molecule Research Therapeutic Modalities, Roche Pharma Research and Early Development (pRED), on: ‘ Bispecific and next-generation antibodies for non-oncology indications such as ophthalmologic and neurologic diseases’.
The Pharma Data
OCTOBER 14, 2020
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
Expert insights. Personalized for you.
52 
Let's personalize your content